Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Behavioural Symptoms in Alzheimer's Disease
2019-002106-52Phase 2Unknown
- Sponsor
- King's College London
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) and Dementia comparing Cannabidiol with Placebo (2 arms). Primary endpoint: Recruitment feasibility. Status: unknown.
02
Drugs
cannabidiol
03
Conditions
Alzheimer's disease (AD)Dementia
Beyond the preview
Go deeper on 2019-002106-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002106-52.